Intratracheal Budesonide for Extremely Preterm Infants

JAMA Author Interviews
11/11/2024 8 min
Intratracheal Budesonide for Extremely Preterm Infants

Listen "Intratracheal Budesonide for Extremely Preterm Infants"

Descargar episodio Ver en sitio original

Episode Synopsis

Preterm birth is the greatest cause of neonatal mortality and morbidity, with infants born extremely preterm at highest risk. Author Brett J. Manley, PhD, the Royal Women's Hospital, Melbourne, Australia, discusses a new study of the effect of intratracheal corticosteroid administration on survival free of bronchopulmonary dysplasia in preterm infants, with JAMA Deputy Editor Tracy A. Lieu, MD, MPH. Related Content: Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants

More episodes of the podcast JAMA Author Interviews

From the JAMA Network: JAMA Research of the Year With Editor in Chief Kirsten Bibbins-Domingo 26/12/2025
The Sequential Organ Failure Assessment (SOFA)-2 Score 29/10/2025
From the JAMA Network: Acetaminophen Use in Pregnancy and Risk of Autism 30/09/2025
From the JAMA Network: AI-Based Analysis for Parkinsonism 30/08/2025
Treatment of Complicated Staphylococcus aureus Bacteremia 13/08/2025
From the JAMA Network: Incidence and Nature of Antidepressant Discontinuation Symptoms 05/08/2025
From the JAMA Network: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension 28/07/2025
Life Support and Outcomes in Patients Admitted to Intensive Care Units 14/04/2025
Increases in Invasive Group A Streptococcal Infections 07/04/2025
Preventive Health Care Among Adults Eligible for Lung Cancer Screening 02/04/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA